Voyageur Pharmaceuticals is the Future of Medical Imaging
Voyageur Pharmaceuticals produces a performance-validated contrast media product that meets industry standards and is a preferred choice among patients.
A single supplier has long dominated the barium contrast industry. Voyageur Pharmaceuticals is now introducing a new, high-quality alternative, offering choice to health care professionals for use in CT scans and fluoroscopy.
Positive Patient Experience and Clinical Outcomes
With an enhanced taste profile, our products improve patient experience and clinical outcomes. Voyageur Pharmaceutical’s contrast mediums give providers and patients an effective choice that delivers positive results.
Voyageur Pharmaceuticals offers five barium contrast agents in its product lineup. In addition, we are actively developing V-Gas Effervescent Granules, an innovative antacid and antiflatulent solution utilized in CT scans. Voyageur is also developing iodine-based contrast media to advance CT and MRI imaging capabilities.
OUR PRODUCT LINEUP
Securing the Future of Contrast Media
Barium sulfate has been the standard for CT scans and fluoroscopy since 1911. In a market defined by complex global supply chains, Voyageur Pharmaceuticals is executing a different strategy: it has secured a pure, pharmaceutical-grade barium sulfate resource in the Canadian Rocky Mountains, capable of supporting the global market for over 50 years. Outside of China, no other pharmaceutical-grade deposit exists, positioning this North American resource to serve Canada, the United States, Mexico, and beyond.
With this asset, Voyageur will be the only company controlling the full supply chain—from raw minerals to finished product—delivering high-quality contrast media at a price point competitors cannot match. Voyageur is applying the same vertically integrated model to iodine-based products, expanding its contrast media portfolio to provide choice, strengthen supply security, and support long-term market growth.
News
Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing
Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
